Blackrock Neurotech celebrates 30,000 patient days


Blackrock Neurotech’s powerful brain-computer interface technology empowers people with paralysis and neurological disorders to perform life-changing tasks and increase their independence

SALT LAKE CITY, June 28, 2022 /PRNewswire/ — Blackrock Neurotech, the leader in brain-computer interface (BCI) technology, has announced a record milestone: 30,000 hospital-based BCI research days, approximately 20 times longer than any other BCI technology implantable reported to date.

“Most people have the perception that implantable BCIs are still in the early days of research, but the fact is that our products are guided by safety and efficacy data dating back to 2004. We restore the function of patients for nearly two decades, as demonstrated by this milestone, and we believe the technology is ready to come out of the lab and into patients’ homes,” said Florian Solzbacher, co-founder and president of Blackrock Neurotech.

Of the people who have participated in implantable BCI research studies – a group that Blackrock calls “BCI Pioneers” – the majority have used Blackrock’s technology. While there may be different methods of implanting BCIs, Blackrock remains committed to the direct-to-brain implant approach, which has demonstrated the greatest functionality of any implant tested in humans. As a BCI pioneer thinks about movement, Blackrock’s interface collects very precise signals from individual neurons in the cortex. These brain signals are then translated into digital commands, allowing pioneers to perform complex functions naturally and intuitively. For the past eighteen years, Blackrock’s state-of-the-art devices have enabled pioneers to perform tasks such as eating, drinking, typing, making art, even control robotic arms– with just their brain signals.

“To move individual fingers and other fine, detailed movements, you really need something that can capture the high-resolution data that a direct approach to the brain allows,” says Ian Burkhart, 31, whose implant Blackrock lasted over seven years and allowed him to regain motor and sensory control of the muscles in his arm and hand. During this period, Ian was able to type, move objects, feel sensations, even play guitar hero.

In terms of safety, Blackrock’s technology has chronic safety and efficacy data cited in 116 peer-reviewed journal articles, and no Serious adverse events reported by the FDA related to the BCI since the beginning of the trials in 2004.

To enhance existing surgical methods, last year Blackrock announced a partnership with industry leader ClearPoint Neuro to develop a portfolio of custom navigation solutions including consumables, hardware, software and robotics that will streamline and adapt the implantation, while reducing the risk of surgical complications. Additionally, Blackrock is working on developing new materials that improve the safety of the device and ensure less impact on surrounding tissue. Blackrock hopes these innovations will help pave the way for more widespread patient adoption in 2023.

“It’s really quite simple: direct data means better data, which means greater potential for fundamental improvement in patient care. Our BCI is currently the only method that has been shown to have utility. long term and restores movement, communication and even sensation to the patient Future applications may include restoration of hearing and vision, treatment or alleviation of pain, reduction of depression – we truly believe the possibilities are endless,” said Marcus Gerhardt, co-founder and CEO of Blackrock Neurotech. “All of these efforts require a continued focus on innovation and partnerships, areas in which we have great progress.”

As for Burkhart, whose implant was removed in 2021 at the end of his study, given the chance he says he would do it again. “Knowing the technology and knowing where it’s going, I would definitely do it again because I know it’s something that would improve my quality of life.”

Blackrock Neurotech plans to submit MoveAgain, their first commercial BCI device, to the FDA in 2022.

About Blackrock Neurotech

Blackrock Neurotech, formerly known as Blackrock Microsystems, is dedicated to the clinical application of brain-computer interface (BCI) technology. Blackrock, founded in 2008, is the world’s leading platform company for BCI technology and the development of implantable solutions that improve human life. Blackrock’s precision electrode technology is at the heart of many global BCI innovations, enabling dozens of early adopters (known as “BCI Pioneers”) SeeAgain, HearAgain, MoveAgain and more. For more information, visit

Press contacts:Sara Batchelder[email protected]LSPR/M for Blackrock Neurotech

Quote Show original content to download multimedia:

SOURCE Blackrock Neurotech


About Author

Comments are closed.